医疗器械企业AngioDynamics Inc（股票代码：ANGO.OQ）发布截至5月31日的季度业绩报告。尽管公司仍处于亏损状态，但多项财务指标表现优于市场预期：经调整后每股亏损0.03美元，较去年同期每股亏损0.06美元显著收窄，且远超华尔街分析师普遍预测的每股亏损0.12美元。值得注意的是，市场预期区间原本位于每股亏损0.17美元至0.09美元之间。
营收数据同样亮眼——本季度实现营业收入8016万美元，同比攀升12.9%，大幅超越7426万美元的市场共识预期。按通用会计准则计算，公司季度每股实际亏损0.15美元，当季净亏损额达605万美元。
资本市场方面，该公司本季度股价累计下跌2.9%，但年初至今仍保持5.1%的涨幅。值得关注的是，分析师群体近期维持对该股的乐观预期：过去三个月盈利预测保持稳定，最近30天内未出现任何评级调整。当前机构共识评级为"买入"，具体包括3个"强力买入"或"买入"建议，无"持有"或卖出类评级。该评级水平与医疗器械及分销行业的同业公司平均共识持平。
根据华尔街最新预测数据，分析师给予AngioDynamics的12个月目标价中位数为16.00美元，较最新收盘价9.63美元存在39.8%的上行空间。历史业绩显示，公司已连续四个季度实现盈利超预期，最近四个报告期每股收益均高于市场预估值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.